AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesAnthropology, Education, Sociology and Social PhenomenaInformation ScienceNamed GroupsHealth Care
Bone Marrow TransplantationTransplantation, HomologousBone MarrowBone NeoplasmsGraft vs Host DiseaseBone Marrow CellsWhole-Body IrradiationLeukemiaAnemia, AplasticBone and BonesTissue DonorsTransplantation ConditioningTransplantation, AutologousTransplantation ChimeraCytomegalovirus InfectionsGraft SurvivalLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHematopoietic Stem Cell TransplantationHematologic NeoplasmsHistocompatibility TestingLeukemia, Myeloid, AcuteImmunosuppressive AgentsRecurrenceHematopoietic Stem CellsHistocompatibilityPrecursor Cell Lymphoblastic Leukemia-LymphomaLymphocyte DepletionBusulfanBone Marrow PurgingTime FactorsNuclear FamilyCyclosporineAcute DiseaseRadiation ChimeraLymphocyte TransfusionBone Marrow DiseasesCombined Modality TherapyTreatment OutcomeTransplantation, IsogeneicImmunosuppressionMice, Inbred C57BLRemission InductionHematopoiesisCyclophosphamideGraft RejectionBone RemodelingT-LymphocytesGraft vs Host ReactionBone Marrow ExaminationRetrospective StudiesSurvival AnalysisCytomegalovirusLeukocyte TransfusionBone Marrow NeoplasmsKidney TransplantationLeukemia, MyeloidHepatic Veno-Occlusive DiseaseImmunocompromised HostMyelodysplastic SyndromesOpportunistic InfectionsHLA AntigensHematologic DiseasesGraft vs Tumor EffectChimeraFatal OutcomeBone DensityColony-Forming Units AssayLymphoma, Non-HodgkinTransplantation ImmunologyMice, Inbred BALB CBone ResorptionSevere Combined ImmunodeficiencyActuarial AnalysisPneumonia, ViralGraft vs Leukemia EffectSpleenSurvival RateCell DifferentiationGanciclovirMycosesLeukocyte CountLiver TransplantationFollow-Up StudiesFlow CytometryAntilymphocyte SerumStem Cell TransplantationDisease-Free SurvivalBlood Group IncompatibilityInfectionMultiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsCells, CulturedPolymerase Chain ReactionAspergillosisGranulocyte Colony-Stimulating FactorHeart TransplantationAntigens, CD34PancytopeniaLeukemia, Myelomonocytic, AcuteMethotrexate
Graft-versus-Hematopoietic stemHSCTGVHDRecipientsAutologous stem cell transChemotherapyMalignanciesBlood and Marrow TransplantationSurvivalPost-transplantMyeloablativePatientsMesenchymalStem cellsRelapseStromal cellsLeukemiaLiverHematologicPediatricClinicalTissueRenalReconstitutionBiopsyCytokineInfusionCellsOrgansPatientMortalityOutcomesCurative therapyMSCsMycophenolate mofetilCellularRejectionComplicationsCancerBlasts
Graft-versus-15
  • In a newly reported study, an experimental antibody treatment largely prevented gastrointestinal acute graft versus host disease (GI-aGVHD) in the intestines of mice and non-human primates (NHPs) given a bone marrow transplant-allogeneic hematopoietic cell transplant (allo-HCT)-but without causing broad immune suppression. (genengnews.com)
  • An acute graft-versus-host disease activity index to predict survival after hematopoietic cell transplantation with myeloablative conditioning regimens. (nature.com)
  • Prospective evaluation for upper gastrointestinal tract acute graft-versus-host disease after hematopoietic stem cell transplantation. (nature.com)
  • Adoptive Allogeneic T-cell therapy (ATCT) might be curative for MM, however current ATCT protocols often lead to graft versus host disease (GvHD). (biomedcentral.com)
  • This includes bone and cartilage repair, cell types into which MSCs readily differentiate, and immune conditions such as graft versus host disease and autoimmune conditions that utilize the MSC's immune suppressive properties. (biomedcentral.com)
  • Clinicians have a new standard for graft-versus-host disease (GVHD) prevention after allogeneic hematopoietic stem cell transplantation, according to results from a phase III study published June 22 in the New England Journal of Medicine . (arkhealthandselfreliance.com)
  • Javier Bolaños-Meade et al, Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis, New England Journal of Medicine (2023). (arkhealthandselfreliance.com)
  • Our hypothesis about a splenic stem cell contributionor maintained survival compared to bone marrow transplants, to PBSCT also derives from the observation that G-CSF mobilizationsalthough graft versus host disease (GVHD) still occurs [1]. (fliphtml5.com)
  • Newer research indicates that other graft-versus-host disease target organs include the immune system (the hematopoietic system , e.g., the bone marrow and the thymus ) itself, and the lungs in the form of immune-mediated pneumonitis . (wikipedia.org)
  • The use of allogeneic hematopoietic cell transplantation (HCT) is the most potent immunotherapeutic treatment for hematologic diseases, but its practical use is impeded by acute and chronic graft-versus-host disease (GvHD). (cryostem.org)
  • Second, the use of the patient's own bone marrow cells for gene replacement does not result in graft-versus-host disease (GVHD), a major complication of current allogeneic transplant. (nih.gov)
  • Characteristics and risk of chronic graft-versus-host disease of liver in allogeneic hematopoietic stem cell transplant recipients. (cdc.gov)
  • Donor-recipient killer immunoglobulin like receptor (KIR) genotype matching has a protective effect on chronic graft versus host disease and relapse incidence following HLA-identical sibling hematopoietic stem cell transplantation. (cdc.gov)
  • Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation. (cdc.gov)
  • Chronic graft-versus-host disease could ameliorate the impact of adverse somatic mutations in patients with myelodysplastic syndromes and hematopoietic stem cell transplantation. (cdc.gov)
Hematopoietic stem5
HSCT6
  • Given the potential importance of MAIT cells in control of microbial infections and protection of epithelial surfaces, we investigated MAIT cell reconstitution in 43 children who underwent hematopoietic stem cell transplantation (HSCT) after myeloablative conditioning for the treatment of malignant hematological disease. (cryostem.org)
  • Recent advances in flow cytometric and molecular measurable residual disease detection have further enhanced modern risk-stratified approaches to chemotherapy and allocation to allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission (CR1) when indicated. (haematologica.org)
  • The ability to correct genetic hematopoietic diseases by gene therapy has a number of advantages over current therapies that involve allogeneic hematopoietic stem cell transplantation (HSCT). (nih.gov)
  • We are evaluating whether allogeneic HSCT can reconstitute normal hematopoiesis in MonoMAC and reverse the hematological abnormalities in MDS, if MDS is present at the time of transplant. (nih.gov)
  • While allogeneic HSCT is the conventional curative treatment for immunodeficiency and MDS, patients with MonoMAC, because of an intact T-cell population and co-existing infection, represent a profile not generally encountered in the setting of allogeneic HSCT. (nih.gov)
  • In the section on aspergillosis, the revised recommendations include the use of a room with high-efficiency particulate air filters rather than laminar airflow as the protective environment for allogeneic HSCT recipients and the use of high-efficiency respiratory-protection devices (e.g. (cdc.gov)
GVHD20
  • The study, headed by researchers at Penn Medicine and Dana-Farber/Boston Children's Cancer and Blood Disorders Center, demonstrated that antibody blockade of the Notch signaling pathway improved post-transplant survival and protected against gastrointestinal GVHD in particular. (genengnews.com)
  • We found that just a single dose of antibodies to block the Notch signaling pathway, given immediately before the transplant, was able to prevent gastrointestinal GVHD, without impairing immune function in the rest of the body," said Ivan Maillard, MD, PhD, a professor of Medicine and vice chief for research in hematology-oncology at the Perelman School of Medicine at the University of Pennsylvania. (genengnews.com)
  • And even when a bone marrow transplant is curative for leukemia or lymphoma, GVHD-in which T cells in the donor graft attack the recipient's own tissues-can still be fatal. (genengnews.com)
  • In experiments with mouse models of GVHD, the researchers showed that blocking a particular Notch activator known as DLL4 effectively prevented GVHD when administered within the first days after transplantation. (genengnews.com)
  • The team confirmed that the Notch pathway involvement in GVHD was conserved across species, and demonstrated in their animal models that just a single dose of the DLL4-blocking antibody given immediately before stem cell transplantation greatly increased survival and prevented signs of GVHD in the intestines, but without causing global immunosuppression. (genengnews.com)
  • Among 1462 patients who had allogeneic hematopoietic cell transplantation (HCT) between January 2000 and December 2005, 116 (7.9%) developed stage 3-4 gut GVHD. (nature.com)
  • The median time for onset of stage 3-4 gut GVHD was 35 (4-135) days after allogeneic HCT. (nature.com)
  • Transplanting only tumor reactive donor T cells that mediate a graft-versus-myeloma (GvM) but not GvHD may overcome this problem. (biomedcentral.com)
  • These data demonstrate that a transplantation protocol involving only selective tumor-reactive donor T cell families is an effective immunotherapy and results in long-term survival in a mouse model of human MM. The results highlight the need to develop similar ATCT strategies for MM patients that result in enhanced survival without symptoms of GvHD. (biomedcentral.com)
  • But a bone marrow transplant can cause GVHD, a serious and life-threatening complication. (arkhealthandselfreliance.com)
  • For decades, researchers in the bone marrow transplant community have been interested in decreasing the rates of GVHD, which occurs when the donor's immune system reacts against the recipient's tissue. (arkhealthandselfreliance.com)
  • As opposed to an organ transplant where the patient's immune system will attempt to reject only the transplanted organ, in GVHD the new or transplanted immune system can attack the entire patient and all organs. (arkhealthandselfreliance.com)
  • The current gold standard to prevent GVHD after bone marrow transplants is a combination of two drugs: a calcineurin inhibitor, such as tacrolimus or cyclosporine, and methotrexate. (arkhealthandselfreliance.com)
  • In the current phase III study, researchers from multiple institutions tested this standard to prevent GVHD against an experimental regimen of three drugs: cyclophosphamide, tacrolimus, and mycophenolate mofetil. (arkhealthandselfreliance.com)
  • Transplantation of DRCC after ionizing radiation exposure proved to be the most effective rescue therapy against acute radiation syndrome, as confirmed by 100% of recipients' survival and expedited recovery of the hematopoietic system without developing GVHD. (aaps1921.org)
  • GvHD is commonly associated with bone marrow transplants and stem cell transplants . (wikipedia.org)
  • The white blood cells present within the transplanted tissue then attack the recipient's body's cells, which leads to GvHD. (wikipedia.org)
  • In contrast to organ/tissue transplant associated GvHD, the incidence of TA-GvHD is increased with HLA matching (first-degree or close relatives). (wikipedia.org)
  • [11] About one-third to one-half of allogeneic transplant recipients will develop acute GvHD. (wikipedia.org)
  • Neither pre-transplant clinical characteristics nor transplant characteristics are reliably predictive of GvHD outcomes. (cryostem.org)
Recipients2
  • Bob has been a major supporter of bone marrow transplant recipients since the time of his own transplant in 1990. (bonemarrow.org)
  • Bronchiolitis obliterans (BO) after LTx was first described in 1984 at Stanford University, Stanford, CA, USA, in heart-lung transplant recipients who showed a progressive decline inforced expiratory volume in one second (FEV 1 ) 3 . (ersjournals.com)
Autologous stem cell trans3
Chemotherapy10
  • These observations that confirmed the therapeutic benefits of cell therapy led to the development of new concepts for the treatment of hematologic malignancies and solid tumors focusing on utilizing well-tolerated non-myeloablative stem cell transplantation as a platform for cell therapy of cancer targeting killer cells against chemotherapy-resistant malignant cells. (wikipedia.org)
  • Treatments for leukemia include chemotherapy, radiation therapy, and stem cell transplants. (medicalnewstoday.com)
  • Chemotherapy, radiation therapy, targeted therapy, and stem cell or bone marrow transplant are common treatment options for leukemia. (medicalnewstoday.com)
  • Autologous transplantation involves extracting a person's stem cells from the bone marrow or blood and freezing them before a person has chemotherapy or radiation therapy. (medicalnewstoday.com)
  • Doctors transplant the donor's stem cells into the individual after chemotherapy or radiation therapy to replace their diseased or damaged stem cells. (medicalnewstoday.com)
  • The objective of the study is to prepare the patient's body before a stem cell transplant by using an antibody-drug instead of radiation/chemotherapy to make transplants safer. (fanconi.org)
  • We report a patient with PNP deficiency, who received HLA-identical sibling marrow without chemotherapy because of disseminated cytomegalovirus (CMV) infection. (frontiersin.org)
  • The treatment options for disease relapse after HCT include withdrawal of immune suppression, chemotherapy, second allogeneic transplant, cytokine and adoptive cell therapy and donor lymphocyte infusion [ 1 ]. (biomedcentral.com)
  • An important and unanswered question concerns the impact of the number of conventional AML chemotherapy induction cycles to achieve first complete remission on transplant outcomes. (ascopost.com)
  • Growing evidence demonstrates that various cancer treatment modalities, including chemotherapy, radiation therapy, targeted therapy, immunotherapy, hormone therapy, stem cell or bone marrow transplant, and surgery [ 3 - 5 ] , cause premature senescence, as reviewed elsewhere [ 6 - 8 ] . (oaepublish.com)
Malignancies3
  • Allogeneic hematopoietic cell transplantation (allo-HCT) has lifesaving potential for patients with hematological malignancies and bone marrow disorders, the authors wrote. (genengnews.com)
  • Classically the disease is manifested by symptoms of diarrhea, flatulence and malabsorption, however, it is also associated with variable systemic manifestations, including metabolic bone disease, diabetes, thyroid dysfunction and lympho-proliferative malignancies [2]. (nursingtermpapers.com)
  • TheIntroduction later step is unique to splenic function since splenectomy results in similar accumulations of naïve B cells, reduction of memory B cells and Treatment of malignancies with allogeneic peripheral blood stem well-known susceptibilities to select infections [12]. (fliphtml5.com)
Blood and Marrow Transplantation3
Survival8
  • Over the last decade, improvements in surgical techniques, lung preservation, immunosuppression, and management of ischaemia/reperfusion injury and infections have made intermediate-term survival after lung transplantation an achievable goal. (ersjournals.com)
  • Over the last decade, improvements in surgical techniques, lung preservation, immunosuppression, and management of ischaemia/reperfusion injury and infections have contributed to increase the 1‐yr patient survival after lung transplantation (LTx) to 70-80% 1 . (ersjournals.com)
  • Mycophenolate mofetil has been demonstrated to inhibit immunologically mediated inflammatory responses in animal models and to inhibit tumor development and prolong survival in murine tumor transplant models. (nih.gov)
  • Retrospective analysis by the Center for International Blood and Marrow Transplant Research (CIBMTR): Prompt complete remission plus consolidation therapy yields improved survival after allogeneic hematopoietic cell transplantation (allo-HCT) for patients with acute myeloid leukemia (AML) receiving a myeloablative conditioning regimen and not a reduced-intensity conditioning regimen. (ascopost.com)
  • Chronic Granulomatous Disease-Associated IBD Resolves and Does Not Adversely Impact Survival Following Allogeneic HCT. (seattlechildrens.org)
  • The Hematopoietic Cell Transplant Comorbidity Index predicts survival after allogeneic transplant for nonmalignant diseases. (seattlechildrens.org)
  • The emphasis was in the use of adult-derived mesenchymal stem cells as transplants to augment host tissue survival and improve functional recovery following SCI. (drexel.edu)
  • In a large French study, patients with greater than 5% blasts in their bone marrow on day 15 had a lower response rate (34% vs 91%), worse disease-free survival, and worse overall survival than patients with low blast counts on day 15. (medscape.com)
Post-transplant5
  • As such, innovative reduced intensity conditioning (RIC) or non-myeloablative stem cell transplantation (NST) was pioneered by Slavin for safer stem cell transplantation for the treatment of malignant and life-threatening non-malignant disorders correctable by using stem cells and post-transplant immunotherapy if indicated for all patients in need. (wikipedia.org)
  • Median age was 58 (IQR 46-57), median time post-transplant was 5 years (IQR 2-10), 61% were male, and 92% had ≥1 underlying comorbidity. (tts.org)
  • The post-transplant course was uneventful. (frontiersin.org)
  • At 4 years of age and 29 months post-transplant, the patient demonstrated normal T-lymphocyte and natural killer cell numbers. (frontiersin.org)
  • The acute or fulminant form of the disease (aGvHD) is normally observed within the first 10 to 100 days post-transplant, [9] [10] and is a major challenge to transplants owing to associated morbidity and mortality. (wikipedia.org)
Myeloablative1
Patients21
  • Persistent nausea and anorexia after marrow transplantation: a prospective study of 78 patients. (nature.com)
  • He created the Sports Legends Golf Classic in Delray Beach, Florida, to benefit the Bone Marrow & Cancer Foundation, raising over 2.5 million dollars for patients. (bonemarrow.org)
  • Since beginning the BMCF in 1992, Christina has dedicated her life to improving the quality of life for cancer patients and bone marrow/Hematopoietic Cell Transplantation (HCT) transplant patients and their families. (bonemarrow.org)
  • Eight patients received conditioning with fludarabine and low-dose total body irradiation followed by hematopoietic cell transplantation from an HLA-matched sibling donor. (aacrjournals.org)
  • Treatment of metastatic renal cell carcinoma with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning with fludarabine/total body irradiation is feasible and may induce tumor regression or stabilization in some patients. (aacrjournals.org)
  • BO and its clinical correlate bronchiolitis obliterans syndrome (BOS) affect up to 50-60% of patients who survive 5 yrs after surgery, irrespective of the type of transplant procedure 1 , 4 - 6 . (ersjournals.com)
  • 12 months = 0) was generated as an approach to classify patients into different risk categories in the purpose to provide guidance to the transplant physician to inform the outcomes to potential patients undergoing 2nd HCT. (biomedcentral.com)
  • Our novel approach of DRCC transplantation may act as a bridging therapy supporting hematopoietic recovery and ameliorating injuries in patients exposed to the harmful effects of radiation. (aaps1921.org)
  • PURPOSE: This phase I/II trial is studying the side effects and best dose of donor natural killer cells when given after a donor stem cell transplant in treating patients with advanced cancer. (bioseek.eu)
  • To assess the safety of donor natural killer (NK) cell infusion after HLA-mismatched/haploidentical allogeneic hematopoietic stem cell transplantation from a familial donor in patients with advanced malignant disorders. (bioseek.eu)
  • Only physicians experienced in immunosuppressive therapy and management of renal, cardiac or hepatic transplant patients should prescribe mycophenolate mofetil. (nih.gov)
  • These criteria plus the absence of extrahepatic and major vessel involvement satisfy the Milan criteria, used to assess suitability of liver transplantation for patients who have cirrhosis and hepatocellular carcinoma. (msdmanuals.com)
  • For patients with liver metastases, transplantation is indicated only for neuroendocrine tumors without extrahepatic growth after removal of the primary tumor. (msdmanuals.com)
  • The second bone marrow infusion was down in 8 patients, including 3 who are still living with mixed chimerism. (ectrx.org)
  • In conclusion, allogeneic BMT or PSCT is curative therapy for the patients with beta-thalassemia major, and it is advised for lethal diseases such as leukemia, severe aplastic anemia, and relapsed lymphoma cases. (ectrx.org)
  • Patients with AML present with symptoms resulting from bone marrow failure, symptoms resulting from organ infiltration with leukemic cells, or both. (medscape.com)
  • MDS is a bone marrow disease of unknown etiology that occurs most often in older patients and manifests as progressive cytopenias that occur over months to years. (medscape.com)
  • Le pourcentage de CD44 dans les lymphocytes T périphériques était significativement plus élevé chez les patients que chez les témoins, comme détecté par la cytométrie en flux. (who.int)
  • En outre, il y avait une aug- mentation significative de la forme soluble du c-kit dans le sérum des patients atteints de pemphigus vulgaire actif par rapport aux témoins. (who.int)
  • Because the chromosomal t(14;18) translocation is found in the majority of patients with follicular lymphoma, bone marrow aspiration and chromosome analysis can also help establish the diagnosis. (medscape.com)
  • Most patients with follicular lymphoma present at an advanced stage, and most patients have bone marrow involvement at diagnosis. (medscape.com)
Mesenchymal5
  • While numerous teams continue to refine and expand the role of bone marrow and cord blood stem cells for their vanguard uses in blood and immune disorders, many others are looking to expand the uses of the various types of stem cells found in bone marrow and cord blood, in particular mesenchymal stem cells, to uses beyond those that could be corrected by replacing cells in their own lineage. (biomedcentral.com)
  • There are many studies involving autologous therapies and some allogenic therapies, based on the recovery of mobilized bone marrow cells, including mesenchymal stem cells (MSCs) and adipose derived stem cells that also include the stromal or adherent cell type that has an MSC phenotype. (biomedcentral.com)
  • Later, Arnold Caplan's group described mesenchymal stem/stromal cells (MSCs) as multipotent mesenchymal cell populations which can differentiate into several tissue types, and demonstrated roles for MSCs in the regeneration of bone, cartilage or ligaments in animal and clinical studies [2-4]. (stemcellslab.net)
  • Pivotal studies by the group of Horwitz in children with osteogenesis imperfecta, an inherited enzyme deficiency of collagen synthesis by mesenchymal cells in bone, opened the field for intravenous use of MSCs. (stemcellslab.net)
  • The transplantation of bone marrow-derived mesenchymal stem cells (BMMSCs) alleviates neuropathology and improves cognitive deficits in animal models with Alzheimer's disease. (biomedcentral.com)
Stem cells6
Relapse3
  • Second allogeneic hematopoietic stem cell transplant (HCT) remains as an option for disease relapse after initial HCT. (biomedcentral.com)
  • Interestingly, thiscell transplants (PBSCTs) from donors given granulocyte-colony- immature peripheral phenotype was similar to bone marrow transplantsstimulating-factor (G-CSF) has decreased relapse rates and improved before G-CSF. (fliphtml5.com)
  • Kinetics and Risk Factors of Relapse after Allogeneic Stem Cell Transplantation in Children with Leukemia: A Long-Term Follow-Up Single-Center Study. (cdc.gov)
Stromal cells1
Leukemia5
Liver4
  • There are three experimental studies on strategies to reduce ischemia reperfusion injury, including use of NRF2 activators in liver (rat), normothermic ex vivo perfusion (pig) or free radical scavengers (PrC-210) in (rat) kidney grafts. (tts.org)
  • 50 transplant centers were included: 318 (66%) kidney or kidney/pancreas, 73 (15.1%) liver, 57 (11.8%) heart, and 30 (6.2%) lung. (tts.org)
  • Liver transplantation is the 2nd most common type of solid organ transplantation. (msdmanuals.com)
  • Second, the rapid proliferation of these cells, along with a reduction in their ability to undergo programmed cell death (apoptosis), results in their accumulation in the bone marrow, the blood, and, frequently, the spleen and liver. (medscape.com)
Hematologic2
  • Hematologic analysis revealed markedly increased peripheral leukocyte counts in DRCC treated animals between day 20th and 60th following transplantation, whereas red blood cell and platelet counts did not differ between groups. (aaps1921.org)
  • To complement The ASCO Post 's continued comprehensive coverage of the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on allogeneic transplantation for hematologic neoplasms in adults. (ascopost.com)
Pediatric3
  • Maillard, together with co-senior and co-corresponding author Leslie S. Kean, MD, PhD, a professor of pediatrics at Harvard Medical School and director of pediatric stem cell transplant at Dana-Farber/Boston Children's Cancer and Blood Disorders Center, and lead author Victor Tkachev PhD, an assistant professor of surgery at Mass General Brigham, have long sought to prevent this fatal complication. (genengnews.com)
  • Four-year data after pediatric renal transplantation: a randomized trial of tacrolimus vs. cyclosporin microemulsion. (findmedarticle.com)
  • Primary focal segmental glomerulosclerosis--long-term outcome after pediatric renal transplantation. (findmedarticle.com)
Clinical2
  • In 1975-1978, Slavin trained in clinical immunology/rheumatology at the Division of Immunology, Stanford University School of Medicine and later on in 1978, trained in clinical bone marrow transplantation under the late E.D. Thomas at the Fred Hutchinson Cancer Research Center in Seattle, Washington. (wikipedia.org)
  • Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. (cdc.gov)
Tissue4
  • Approximately 300 mg of phosphate per day enters and exits bone tissue. (medscape.com)
  • Laboratory investigations confirmed a Immunoglobulin A (IgA) anti-tissue transglutaminase antibodies (IgA-tTG) was markedly elevated to more than 300 u/ml, colonoscopy was normal, Bone mass densitometry revealed osteopenia and hypercellular bone marrow on bone marrow biopsy. (nursingtermpapers.com)
  • HSCRB research intersects with immunology in a range of contexts, from bone marrow transplants to tissue repair to autoimmunity. (harvard.edu)
  • eg, bone, bone marrow, and skin grafts) Genetically identical (syngeneic [between monozygotic twins]) donor tissue (isografts) Genetically. (msdmanuals.com)
Renal1
Reconstitution1
  • The aim of this study was to test efficacy of ex-vivo created donor-recipient chimeric cells (DRCC) in reconstitution of bone marrow compartment following total body γ-irradiation (TBI). (aaps1921.org)
Biopsy1
  • The workup for AML includes blood tests, bone marrow aspiration and biopsy (the definitive diagnostic tests), and analysis of genetic abnormalities. (medscape.com)
Cytokine1
  • Effects of hematopoietic stem cell adhesion on marrow stromal cell cytokine p. (rochester.edu)
Infusion2
  • We used an MHC-matched/miHA-disparate B10.D2 → Balb/c bone marrow transplantation (BMT) murine model and MOPC315.BM MM cells to develop an ATCT protocol consisting of total body irradiation, autologous-BMT and infusion of selective, myeloma-reactive lymphocytes of T cell receptor (TCR) Vβ 2, 3 and 8.3 families (MM-auto BMT ATCT). (biomedcentral.com)
  • RATIONALE: Giving an infusion of natural killer cells from a donor after a donor stem cell transplant may help kill any remaining cancer cells after the transplant. (bioseek.eu)
Cells13
  • Working model showing how inhibiting Notch signaling in T cells leads to less conventional T cells and more regulatory T cells in the gut after stem cell transplant. (genengnews.com)
  • Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. (ous-research.no)
  • Pre-stimulation ex vivo of allogeneic T cells by exposure to MOPC315.BM MM cells in the presence of IL-2, anti-CD3 and anti-CD28 resulted in expansion of the myeloma-reactive T cell TCRVβ 2, 3 and 8.3 subfamilies. (biomedcentral.com)
  • To test this rationale, we used the allogeneic B10.D2 → Balb/c BMT model with MOPC315.BM myeloma cells. (biomedcentral.com)
  • Also, for our bone marrow transplant readership, scientists report on the use of purified CD34+CD90+CD45RA- cells in a non-human primate model for allogeneic hematopoietic stem cell transplantation. (tts.org)
  • In the 1970s, Friedenstein and colleagues [1] first reported that locally applied culture-expanded populations of bone marrow stroma-derived fibroblastic cells remained at their injection sites under the kidney capsule, where an ectopic hematopoiesis was initiated. (stemcellslab.net)
  • In these studies, however, transplanted cells were followed, if at all, at the site of transplantation, and biodistribution was not an issue. (stemcellslab.net)
  • DRCC were created by ex-vivo fusion of bone marrow cells derived from fully MHC mismatched LEW (RT1l) and ACI (RT1a) donors. (aaps1921.org)
  • Cells presenting double staining were transplanted in a dose 10-12 x 106. (aaps1921.org)
  • We have successfully created DRCC by ex-vivo fusion of bone marrow derived cells. (aaps1921.org)
  • One goal of research at HSCRB is to apply this knowledge to engineer cells to protect them in the settings of allogeneic transplantation and autoimmunity. (harvard.edu)
  • We have used this model to test retroviral and foamy viral gene transfer into the bone marrow cells of dogs. (nih.gov)
  • The underlying pathophysiology in AML consists of a maturational arrest of bone marrow cells in the earliest stages of development. (medscape.com)
Organs3
  • A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. (curehunter.com)
  • A shift in the nature of complications from early to late graft dysfunction has been similarly observed after transplantation of other solid organs 2 . (ersjournals.com)
  • Advantages of living donation for the recipient include shorter waiting times and shorter cold ischemic times for explanted organs, largely because transplantation can be scheduled to optimize the patient's condition. (msdmanuals.com)
Patient4
  • Patient must not be on other experimental therapies at the time and not have active cancers or concerns for high-risk bone marrow disease. (fanconi.org)
  • Her passion for patient support and advocacy lead to founding the Bone Marrow & Cancer Foundation. (bonemarrow.org)
  • As a review article, we have a timely overview on COVID-19 in kidney transplantation related to epidemiology, patient management and impact. (tts.org)
  • In other areas of transplantation research, we have an experimental article on preclinical allogeneic nerve transplantation, and a survey-based study on developing a tool-set for maximizing proper patient access to organ transplantation programs. (tts.org)
Mortality3
  • Reduced mortality after allogeneic hematopoietic-cell transplantation. (nature.com)
  • Disadvantages to the donor include mortality risk of 1/600 to 700 (compared with 1/3300 in living-donor kidney transplantation) and complications (eg, bile leakage, bleeding) in up to one fourth. (msdmanuals.com)
  • Early mortality is often associated with bone marrow failure, infections, fatal pulmonary complications, or malignancy. (medscape.com)
Outcomes1
Curative therapy1
MSCs3
  • Therefore, the authors concluded that transplantation of isolated healthy allogeneic MSCs might cure the disease. (stemcellslab.net)
  • This implies homing of transplanted MSCs to sites in bone marrow and/or bone. (stemcellslab.net)
  • In a second study [6], these authors showed that autologous, enzyme-deficient MSCs transduced with a copy of the intact gene resulted in normal collagen production in bone cavities. (stemcellslab.net)
Mycophenolate mofetil1
  • Mycophenolate mofetil also inhibited proliferative arteriopathy in experimental models of aortic and cardiac allografts in rats, as well as in primate cardiac xenografts. (nih.gov)
Cellular1
  • Saline as well as cellular therapeutics were delivered into the femoral bone at 6 hours following TBI. (aaps1921.org)
Rejection1
  • in older children and adults, these transplants are not used because there is a high risk of rejection and bile duct damage (ductopenia) with cholestasis, which requires retransplantation. (msdmanuals.com)
Complications1
  • To date, preclinical studies have relied heavily on mouse allo-HCT models, but these are not always ideal and, as the team pointed out, "… mouse allo-HCT differs from human allo-HCT in terms of transplant conditioning, supportive care, and complications. (genengnews.com)
Cancer8
  • Upon returning to Jerusalem, he opened the first Bone Marrow Transplantation Center at the Hadassah University Hospital, which was later recognized as Israel's National Bone Marrow Transplantation and & Cancer Immunotherapy Center. (wikipedia.org)
  • Baxter International recognized the potential of cell therapy and signed an agreement which resulted in significant investment with Slavin at Hadassah Medical Center for further development of new approaches based on cell therapy for the treatment of cancer, autoimmune diseases, and organ transplantation based on new methods for regulation rather than non-specific suppression of the immune system. (wikipedia.org)
  • Bob Fishman is a founding member of the Bone Marrow & Cancer Foundation's Board of Directors. (bonemarrow.org)
  • When not advocating for the Bone Marrow & Cancer Foundation, Bob is a producer and director at CBS Sports. (bonemarrow.org)
  • Charlotte is a Trustee of Thomas Jefferson BMCF at Monticello, the Bone Marrow & Cancer Foundation, American Corporate Partners, The Madoo Conservancy, a member of the International Council of Hillwood Estate, Museum and Gardens, and on the Advisory Board of The New York School of Interior Design where she holds an Honorary Doctorate Degree. (bonemarrow.org)
  • As Treasurer of the Board of Directors, Andy Robin plays an integral part in the efforts of the Bone Marrow & Cancer Foundation. (bonemarrow.org)
  • Christina Merrill is President and Chief Executive Officer of the Bone Marrow & Cancer Foundation. (bonemarrow.org)
  • The new standard allows transplants to be less toxic," says lead study author Javier Bolaños-Meade, M.D., professor of oncology at the Johns Hopkins Kimmel Cancer Center. (arkhealthandselfreliance.com)
Blasts1
  • Most AML subtypes are distinguished from other related blood disorders by the presence of more than 20% blasts in the bone marrow. (medscape.com)